CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
26 Juli 2023 - 1:00PM
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment
of life-threatening conditions in the intensive care unit and
cardiac surgery using blood purification, will report second
quarter 2023 operating and financial results after the market close
on Tuesday, August 1st, 2023. CytoSorbents’ management will host a
live presentation webcast and a question and answer session at
4:30PM EDT the same day.
Webcast Details:Date: Tuesday, August 1st,
2023Time: 4:30 PM Eastern Webcast link:
https://edge.media-server.com/mmc/p/ux9gjyvu
Conference Call Details:For those participants
who cannot join by webcast, we are pleased to offer a conference
call option accessible through the following link:
https://register.vevent.com/register/BIb5f023a4734446ce8e778065c2d484d9
- Click on the call link and complete the online registration
form.
- Upon registering you will receive the dial-in info and a unique
PIN to join the call, as well as an email confirmation with the
details.
- Select a method for joining the call.
- Dial-In: A dial in number and unique PIN are displayed to
connect directly from your phone.
- Call Me: Enter your phone number and click “Call Me” for an
immediate callback from the system.
For either the webcast or conference call, it is
recommended that participants log or dial in approximately 10
minutes prior to the start of the call.
An archived recording and written transcript of
the conference call will be available under the Investor Relations
section of the Company’s website at
http://cytosorbents.com/investor-relations/financial-results/
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in the
treatment of life-threatening conditions in the intensive care unit
and in cardiac surgery through blood purification. Its lead
product, CytoSorb®, is approved in the European Union and
distributed in 75 countries worldwide. It is an extracorporeal
cytokine adsorber that reduces "cytokine storm" or "cytokine
release syndrome" in common critical illnesses that can lead to
massive inflammation, organ failure and patient death. In these
diseases, the risk of death can be extremely high, and there are
few, if any, effective treatments. CytoSorb is also used during and
after cardiothoracic surgery to remove antithrombotic drugs and
inflammatory mediators that can lead to postoperative
complications, including severe bleeding and multiple organ
failure. At the end of Q1 2023, more than 203,000 CytoSorb devices
had been used cumulatively. CytoSorb was originally launched in the
European Union under CE mark as the first cytokine adsorber.
Additional CE mark extensions were granted for bilirubin and
myoglobin removal in clinical conditions such as liver disease and
trauma, respectively, and for ticagrelor and rivaroxaban removal in
cardiothoracic surgery procedures. CytoSorb has also received FDA
Emergency Use Authorization in the United States for use in adult
critically ill COVID-19 patients with impending or confirmed
respiratory failure. The DrugSorb™-ATR antithrombotic removal
system, based on the same polymer technology as CytoSorb, also
received two FDA Breakthrough Device Designations, one for the
removal of ticagrelor and another for the removal of the direct
oral anticoagulants (DOAC) apixaban and rivaroxaban in a
cardiopulmonary bypass circuit during urgent cardiothoracic
procedures. The Company is currently conducting the FDA-approved,
randomized, controlled STAR-T (Safe and Timely Antithrombotic
Removal-Ticagrelor) study, and has now completed patient enrollment
at approximately 30 centers in U.S. and Canada to evaluate whether
intraoperative use of DrugSorb-ATR can reduce the perioperative
risk of bleeding in patients receiving ticagrelor and undergoing
cardiothoracic surgery. This pivotal study is intended to support
U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in
this application.
CytoSorbents’ purification technologies are
based on biocompatible, highly porous polymer beads that can
actively remove toxic substances from blood and other bodily fluids
by pore capture and surface adsorption. Its technologies have
received non-dilutive grant, contract, and other funding of
approximately $48 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The
Company has numerous marketed products and products under
development based upon this unique blood purification technology
protected by many issued U.S. and international patents and
registered trademarks, and multiple patent applications pending,
including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™,
HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR,
ContrastSorb, and others. For more information, please
visit the Company’s websites
at www.cytosorbents.com and www.cytosorb.com or
follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking
statements intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited
to, statements about our plans, objectives, future targets and
outlooks for our business, statements about potential exposures
resulting from our cash positions, representations and contentions,
and are not historical facts and typically are identified by use of
terms such as “may,” “should,” “could,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue” and similar words, although some forward-looking
statements are expressed differently. You should be aware that the
forward-looking statements in this press release represent
management’s current judgment and expectations, but our actual
results, events and performance could differ materially from those
in the forward-looking statements. Factors which could cause or
contribute to such differences include, but are not limited to, the
risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 9, 2023, as updated by the risks reported in our
Quarterly Reports on Form 10-Q, and in the press releases and other
communications to shareholders issued by us from time to time which
attempt to advise interested parties of the risks and factors which
may affect our business. We caution you not to place undue reliance
upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on
Facebook and
Twitter
U.S. Company Contact:Kathleen Bloch, Interim
CFO305 College Road EastPrinceton, NJ 08540+1 (732) 398-5429
kbloch@cytosorbents.com
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024